Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexeon MedSystems Inc.

Latest From Nexeon MedSystems Inc.

Puerto Rico Bolsters Its Life-Sciences Hub With R&D, Start-Up Initiatives

In the past year, Puerto Rico formed a consortium of clinical trial sites, launched a funding program for entrepreneurs and created a technology transfer office – all achievements touted at the Biolatam biotech conference in San Juan.

Medical Device Puerto Rico

Start-Up Quarterly Statistics, Q2 2010

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
BioPharmaceutical Medical Device

The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs

Growth by innovation is almost considered a birthright in interventional cardiology, and based on presentations at this year's Transcatheter Cardiovascular Therapeutics meeting, held this September in San Francisco, it seems clear that innovation still reigns supreme in this specialty. However, as in other medical device markets, ongoing economic and regulatory pressures are taking their toll, particularly in the drug-eluting stent market, as the field adjusts to a new era of cost control and economic uncertainty.
Medical Device

Start-Up Quarterly Statistics, Q4 2008

Highlights from the Q4 2008 review of start-up dealmaking: Fundraising in the biopharma, med-device, and in vitro diagnostics industries totaled $551 million, a 41% decrease from 3Q and just another indication of the tough economic times. Of the three acquisitions done this quarter--two in biopharma and one in devices--only one had a disclosed value. About one-third of the 19 biopharma alliances were in the cancer therapy area.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Paragon Intellectual Properties LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nexeon MedSystems Inc.
  • Senior Management
  • Will Rosellini, CEO
    Chris Miller, CFO
    Brian Blischak, President & Chief Commercial Officer
    Mark Bates, MD, DSci, Founder & Chief Innovation Officer
  • Contact Info
  • Nexeon MedSystems Inc.
    Phone: (214) 414-0454
    Ste. 1002
    Lexington, KY 40511